Tamibarotene for the treatment of acute promyelocytic leukemia

Bibliography

• Jabbour E, Cortes J, Ravandi F, et al. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol 2013;50:271-83
   PubMed Web of Science ®Google Scholar
• Farooqui MZH, Wiestner A. Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opin Orphan Drugs 2013;1:925-33
   Web of Science ®Google Scholar
• Lubanski PM, Czuczman MS. Lenalidomide for the treatment of B-cell lymphoma. Expert Opin Orphan Drugs 2013;1:651-9
   Web of Science ®Google Scholar
• Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993;329:177-89
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: WHO classification of tumours of haematopoietic and lymphoid tissues. IARC; Lyon: 2008. p. 110-23
   Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15
   PubMed Web of Science ®Google Scholar
• Fenaux P, Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-9
   PubMed Web of Science ®Google Scholar
• Ohno R, Yoshida H, Fukutani H, et al. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993;7:722-7
   Google Scholar
• Gamell C, Jan Paul P, Haupt Y, Haupt S. PML tumour suppression and beyond: therapeutic implications. FEBS Lett 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 2013;210:2793-802
   PubMed Web of Science ®Google Scholar
• de The H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990;347:558-61
   PubMed Web of Science ®Google Scholar
• de The H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66:675-84
   PubMed Web of Science ®Google Scholar
• Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993;329:177-89
   PubMed Web of Science ®Google Scholar
• Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643-53
   PubMed Web of Science ®Google Scholar
• Ohno R, Ohnishi K, Takeshita A, et al. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia 1994;8:S64-9
   Web of Science ®Google Scholar
• Duprez E, Ruchaud S, Houge G, et al. A retinoid acid ‘resistant’ t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia 1992;6:1281-7
   PubMed Web of Science ®Google Scholar
• Warrell RP Jr. Retinoid resistance in acute promytlocytic leukemia: new mechanisms, strategies, and implications. Blood 1993;82:1949-53
   PubMed Web of Science ®Google Scholar
• Ruchaud S, Duprez E, Gendron MC, et al. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc Natl Acad Sci USA 1994;91:8428-32
   PubMed Web of Science ®Google Scholar
• Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002;16:1940-58
   PubMed Web of Science ®Google Scholar
• Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol 2013;97:717-25
   PubMed Web of Science ®Google Scholar
• Muindi J, Frankel SR, Miller WH Jr, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 1992;79:299-303
   PubMed Web of Science ®Google Scholar
• White JA, Beckett-Jones B, Guo YD, et al. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J Biol Chem 1997;272:18538-41
   PubMed Web of Science ®Google Scholar
• Kizaki M, Ueno H, Yamazoe Y, et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 1996;87:725-33
   PubMed Web of Science ®Google Scholar
• Matsushita H, Kizaki M, Kobayashi H, et al. Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukemic cells. Blood 1998;91:2452-8
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shigeno K, Shinjo K, et al. All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance. Leuk Lymphoma 2001;42:739-46
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Naito K, et al. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br J Haematol 2000;108:90-2
   PubMed Web of Science ®Google Scholar
• Delva L, Cornic M, Balitrand N, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993;82:2175-81
   PubMed Web of Science ®Google Scholar
• Cornic M, Delva L, Castaigne S, et al. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 1994;8:s16-19
   PubMed Web of Science ®Google Scholar
• Shao W, Benedetti L, Lamph WW, et al. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 1997;89:4282-9
   PubMed Web of Science ®Google Scholar
• Kitamura K, Kiyoi H, Yoshida H, et al. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia. Leukemia 1997;11:1950-6
   PubMed Web of Science ®Google Scholar
• Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998;92:374-82
   PubMed Web of Science ®Google Scholar
• Nason-Burchenal K, Allopenna J, Begue A, et al. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood 1998;92:1758-7
   PubMed Web of Science ®Google Scholar
• Marasca R, Zucchini P, Galimberti S, et al. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica 1999;84:963-8
   PubMedGoogle Scholar
• Duprez E, Benoit G, Flexor M, et al. A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia 2000;14:255-61
   PubMedGoogle Scholar
• Cote S, Zhou D, Bianchini A, et al. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 2000;96:3200-8
   PubMedGoogle Scholar
• Gallagher RE, Moser BK, Racevskis J, et al. Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood 2012;120:2098-108
   PubMed Web of Science ®Google Scholar
• Mizojiri K, Okabe H, Sugeno K, et al. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 1st communication: absorption, distribution, metabolism and excretion after topical application and subcutaneous administration in rats. Arzneimittelforschung 1997;47:59-69
   PubMedGoogle Scholar
• Ohnishi K. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol 2007;12:313-17
   PubMed Web of Science ®Google Scholar
• Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60
   PubMed Web of Science ®Google Scholar
• Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Yoshida H, Shigeno K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002;16:617-22
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-21
   PubMed Web of Science ®Google Scholar
• Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010;28:1047-53
   PubMed Web of Science ®Google Scholar
• Takeshita A. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia. Int J Hematol 2013;97:703-16
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Naito K, et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005;19:1306-11
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;104:1995-9
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Naito K, et al. Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent. Int J Hematol 2005;82:445-8
   PubMed Web of Science ®Google Scholar
• Kagechika H, Kawachi E, Hashimoto Y, et al. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 1988;31:2182-92
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Kagechika H, Kawachi E, et al. Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. J Cancer Res Clin Oncol 1995;121:696-8
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Z, Jiang Y, et al. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation. Drug Deliv 2014. [Epub ahead of print]
   Google Scholar
• López-Pedrera C, Barbarroja N, Buendía P, et al. Promyelocytic leukemia retinoid signaling targets regulate apoptosis, tissue factor and thrombomodulin expression. Haematologica 2004;89:286-95
   PubMed Web of Science ®Google Scholar
• Ishida S, Shigemoto-Mogami Y, Shinozaki Y, et al. Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL60 cell differentiation reveald by DNA microarray analysis. Biochem Pharmacol 2004;68:2177-86
   PubMed Web of Science ®Google Scholar
• Jimi S, Mashima K, Matsumoto T, et al. RAR alpha is a regulatory factor for Am80-induced cell groth inhibition of hematologic malignant cells. Int J Oncol 2007;31:397-404
   PubMed Web of Science ®Google Scholar
• Uruno A, Noguchi N, Matsuda K, et al. All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta. J Leukoc Biol 2011;90:235-47
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shibata Y, Shinjo K, et al. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am 80. Ann Intern Med 1996;124:893-6
   PubMed Web of Science ®Google Scholar
• Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997;90:967-73
   PubMed Web of Science ®Google Scholar
• Asou N, Adachi K, Tamura U, et al. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 2001;48:S65-71
   PubMed Web of Science ®Google Scholar
• Kitamura K, Kiyoi H, Yoshida H, et al. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Cancer Chemother Pharmacol 1997;40:S36-41
   Google Scholar
• Ohata K, Yamazaki H, Asakuta H, et al. Tamibarotene-induced low-grade reversible intravascular coagulation in a patients with acute promyelocytic leukemia. Thromb Res 2012;129:213-14
   PubMedGoogle Scholar
• Nippon Shinyaku Drug information. Amnolake. Tablet 2mg. Available from: http://www.info.pmda.go.jp/go/pack/4291014F1021_1_09/2009
   Google Scholar
• Maeda Y, Yamaguchi T, Hijikata Y, et al. Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia. J Cancer Res Clin Oncol 2008;134:673-7
   PubMed Web of Science ®Google Scholar
• Fredly H, Ersvær E, Kittang AO, et al. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics 2013;5:13
   PubMed Web of Science ®Google Scholar
• Naina HV, Levitt D, Vusirikala M, et al. Successful treatment of relapsed and refractory extramedually acute promyelocytic leukemia with tamibarotene. J Clin Oncol 2011;29:e534-6
   Google Scholar
• Di Veroli A, Ramadan SM, Divona M, et al. Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene. Br J Haematol 2010;151:99-101
   PubMedGoogle Scholar
• Shinjo K, Takeshita A, Ohnishi K, et al. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid. Int J Hematol 2000;72:470-3
   PubMedGoogle Scholar
• Fujita H, Asou N, Iwanaga M, et al. Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. Cancer Sci 2013;104:1339-45
   PubMedGoogle Scholar
• Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005;82:224-9
   PubMed Web of Science ®Google Scholar
• Shinagawa K, Ohtake S, Sakura T, et al. A Phase III Study of New Synthetic Retinoid Tamibarotene (Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL): Japan Adult Leukemia Study Group (JALSG) APL204 Study [abstract]. Blood 2012;120:#410
   Google Scholar
• Shinagawa K, Yanada M, Sakura T, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol 2014; In press
   PubMedGoogle Scholar